SCHEMBL844968

SCHEMBL844968

NC(=O)c1ccc(C(F)(F)F)[nH]c1=O

nearest known ligand 0.51

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 18/20 0.51
HSD17B1 P14061 3/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3081670 0.86 HSD17B2 (0.42) HSD17B2HSD17B1
SCHEMBL3094841 0.86 HSD17B2 (0.40) HSD17B2HSD17B1
SCHEMBL22868076 0.86 HSD17B2 (0.42) HSD17B2HSD17B1
SCHEMBL3077344 0.83 HSD17B2 (0.52) HSD17B2HSD17B1
SCHEMBL3071478 0.83 HSD17B2 (0.40) HSD17B2HSD17B1
SCHEMBL4898548 0.83 HSD17B2 (0.40) HSD17B2HSD17B1
SCHEMBL19616295 0.81 HSD17B2 (0.54) HSD17B2HSD17B1
SCHEMBL19178226 0.81 HSD17B2 (0.51) HSD17B2HSD17B1
SCHEMBL19178227 0.78 HSD17B2 (0.48) HSD17B2HSD17B1
SCHEMBL29628486 0.77 HSD17B2 (0.48) HSD17B2HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 180 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US claimed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN claimed
EP-2334175-B1 PHENYL-SUBSTITUTED BICYCLOOCTANE 1,3 DIONE DERIVATIVES BAYER IP GMBH (DE) 2017-03-01 EP claimed
EP-2635550-B1 PHENYL-SUBSTITUTED BICYCLOOCTANE-1,3-DIONE-DERIVATIVES BAYER IP GMBH (DE) 2016-01-27 EP claimed
US-9204640-B2 2-acyloxy-pyrrolin-4-ones BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-08 US claimed
US-9198432-B2 1,2,4-triazolyl-substituted ketoenols BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-12-01 US claimed
EP-2681191-B1 2-ACYLOXY-PYRROLIN-4-ONES BAYER IP GMBH (DE) 2015-09-02 EP claimed
EP-2534147-B1 SPIROHETEROCYCLIC-SUBSTITUTED TETRAMIC ACID DERIVATIVES BAYER IP GMBH (DE) 2015-06-17 EP claimed
US-8946124-B2 Substituted 3-(biphenyl-3-yl)-8,8-difluoro-4-hydroxy-1-azaspiro[4.5]dec-3-en-2-ones for therapy and halogen-substituted spirocyclic ketoenols BAYER INTELLECTUAL PROPERTY GMBH (DE) 2015-02-03 US claimed
EP-3994125-B1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMA (US) 2025-12-24 EP disclosed
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS NOVARTIS AG (CH) 2024-10-31 US disclosed
US-20240299402-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF REGENERON PHARMACEUTICALS, INC. (US) 2024-09-12 US disclosed
CN-117980292-A Substituted pyridone compounds for the treatment of orthomyxoviral infections 诺华股份有限公司 2024-05-03 CN disclosed
US-11957687-B2 Modulators of HSD17B13 and methods of use thereof REGENERON PHARMACEUTICALS, INC. (US) 2024-04-16 US disclosed
EP-1987718-A1 Utilisation of pyridine-2-oxy-3-carbon amides as safener Bayer CropScience AG (DE) 2008-11-05 EP disclosed
US-20080269059-A1 PYRIDINECARBOXAMIDES, USEFUL-PLANT-PROTECTING COMPOSITION COMPRISING THEM AND PROCESSES FOR THEIR PREPARTION AND THEIR USE BAYER CROPSCIENCE AG (DE) 2008-10-30 US disclosed
US-20080269052-A1 USE of PYRIDINE-2-OXY-3-CARBOXAMIDES AS SAFENERS BAYER CROPSCIENCE AG (DE) 2008-10-30 US disclosed
US-20080269052-A1 USE of PYRIDINE-2-OXY-3-CARBOXAMIDES AS SAFENERS BAYER CROPSCIENCE AG (DE) 2008-10-30 US disclosed
US-20080269052-A1 USE of PYRIDINE-2-OXY-3-CARBOXAMIDES AS SAFENERS BAYER CROPSCIENCE AG (DE) 2008-10-30 US disclosed
EP-1982978-A1 PYRIDONE DERIVATIVE AND HERBICIDE KUMIAI CHEMICAL INDUSTRY CO., LTD. (JP) 2008-10-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269052-A1 USE of PYRIDINE-2-OXY-3-CARBOXAMIDES AS SAFENERS CBR3, CBR1, CYP4Z1 HSD17B2 3126/4885HSD17B1 3020/4885
US-20240299402-A1 MODULATORS OF HSD17B13 AND METHODS OF USE THEREOF HSD17B3, HSD17B11, HSD17B1 HSD17B2 5/4885HSD17B1 3/4885
US-20080269059-A1 PYRIDINECARBOXAMIDES, USEFUL-PLANT-PROTECTING COMPOSITION COMPRISING THEM AND PROCESSES FOR THEIR PREPARTION AND THEIR USE CYC1, PYCR1, CBR3 HSD17B2 4644/4885HSD17B1 4494/4885
US-11957687-B2 Modulators of HSD17B13 and methods of use thereof HSD17B3, HSD17B11, HSD17B1 HSD17B2 5/4885HSD17B1 3/4885
US-20240360082-A1 SUBSTITUTED PYRIDONE COMPOUNDS USEFUL TO TREAT ORTHOMYXOVIRUS INFECTIONS PNPO, PDXK, PLPBP HSD17B2 2882/4885HSD17B1 2274/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.